Protalix Biotherapeutics Inc
PLX1.495USD
+0.045+3.10%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
116.81M시가총액
29.89P/E TTM
자세한 내용은 Protalix Biotherapeutics Inc 회사
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
회사 정보
종목 코드 PLX
회사 이름Protalix Biotherapeutics Inc
상장일Sep 06, 2010
CEOMr. Dror Bashan
직원 수207
유형Ordinary Share
회계 연도 종료Sep 06
주소2 University Plaza
도시HACKENSACK
증권 거래소Euronext Paris
국가United States of America
우편 번호07601
전화12016969345
웹사이트https://protalix.com/
종목 코드 PLX
상장일Sep 06, 2010
CEOMr. Dror Bashan
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 23
마지막 업데이트: Wed, Jul 23
주주
주주 유형
주주
주주
비율
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
주주
주주
비율
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
주주 유형
주주
비율
Corporation
6.22%
Investment Advisor
4.67%
Individual Investor
4.18%
Hedge Fund
3.67%
Investment Advisor/Hedge Fund
2.30%
Research Firm
0.82%
Pension Fund
0.26%
Venture Capital
0.05%
Other
77.84%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
182
17.64M
22.16%
+1.73M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
2023Q1
95
13.57M
27.32%
-11.07M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
HIR Investments Ltd
4.71M
5.92%
--
--
Apr 30, 2025
Bashan (Dror)
2.28M
2.87%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.19M
1.49%
+70.95K
+6.35%
Mar 31, 2025
Millennium Management LLC
963.01K
1.21%
+575.09K
+148.25%
Mar 31, 2025
Susquehanna International Group, LLP
858.65K
1.08%
+858.65K
--
Mar 31, 2025
Northern Trust Global Investments Limited
683.30K
0.86%
-46.98K
-6.43%
Mar 31, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Marshall Wace LLP
615.09K
0.77%
+513.19K
+503.62%
Mar 31, 2025
Connor, Clark & Lunn Investment Management Ltd.
482.88K
0.61%
+482.88K
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Franklin US Small Cap Multifactor Index ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis International Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
더 보기
iShares Micro-Cap ETF
비율0.02%
iShares Russell 2000 Growth ETF
비율0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0.01%
Franklin US Small Cap Multifactor Index ETF
비율0.01%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
Global X Russell 2000 ETF
비율0%
iShares Russell 2000 Value ETF
비율0%
Avantis International Small Cap Equity ETF
비율0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
